Is Suraksha Diagno. overvalued or undervalued?

As of 14 October 2025, the valuation grade for Suraksha Diagnostics has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this assessment: the PE ratio stands at 45.39, the Price to Book Value is 7.08, and the EV to EBITDA is 18.26, all of which are significantly higher than industry norms.
In comparison to its peers, Suraksha Diagnostics' PE ratio is notably lower than that of Max Healthcare, which has a PE of 93.68, and higher than Apollo Hospitals, which is valued at 70.7. The PEG ratio for Suraksha is 0.00, suggesting a lack of growth expectations compared to its price, further reinforcing the overvaluation stance. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -22.4% compared to the Sensex's 4.98%, which underscores the potential disconnect between its current valuation and market performance.